#regenerative medicine #Conexeu Sciences #Nasdaq CNXU

Conexeu Sciences Strengthens Board for Commercialization Ambitions

In an exciting development following its recent debut on the Nasdaq, Conexeu Sciences Inc. has expanded its board of directors as part of a strategic move to enhance its commercial capabilities in the realm of regenerative medicine. The company, which specializes in regenerative tissue technology, has positioned itself at the forefront of a medical frontier that promises to revolutionize how we approach tissue repair and regeneration.

A New Board for a New Era

On June 15, 2026, Conexeu expanded its board from six to nine members, a clear indication of its intent to transition from a preclinical scientific endeavor to a commercially viable enterprise. This board restructuring includes prominent figures hailing from Fortune 500 companies with vast experience in finance, mergers and acquisitions, and commercialization—all crucial areas for a company seeking to establish a foothold in a competitive market.

Among the new members is Ana Bastiani-Posner, C-suite executive with over two decades of leadership experience. Currently serving as Executive Vice President and CFO at Kyowa Kirin North America, she brings invaluable financial expertise. April Burke, another new director, adds her experience as Executive Vice President and CFO of Lucid Hearing, further enriching the company's financial strategy.

Andrew Costa joins as a well-respected investor and operator with over fifteen years in private equity and investment banking. His role as chair of the Audit Committee will be pivotal in steering the financial governance of Conexeu as it moves into this new phase. Furthermore, co-founder David Bogart has been promoted to Chief Commercial Officer, signaling the company’s focus on operational strategy and execution.

Beyond these appointments, Melinda Farina, known as